Rezūm steam ablation therapy for benign prostatic hyperplasia: Initial results from the United Kingdom

By: Johnston M.1, Shah T.2, Emara A.1, Gehring T.1, Farmer T.1, Nedas T.G.1, Rajkumar G.1, McFarlane A.2, Winkler M.2, El-Husseiny T.2, Ahmed H.U.2, Hindley R.G.1

1Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, 2Imperial College London, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation

Evaluation of outcome of transurethral needle ablation (TUNA) for treating symptomatic BPH: A 10-year experience

By: Haroun H., El-Tatawy H., Soliman M.G., Ragab M., Tawfik A., Sabaa M.
Tanta University, Faculty of Medicine, Dept. of Urology, Tanta, Egypt

Aims and objectives of this presentation

The prostatic urethral lift (Urolift) versus the convection water vapor ablation (Rezūm) for minimally invasive treatment of BPH: A comparison of improvements and durability in 3-year clinical outcomes

By: Shepherd S.1, Saadat S.H.1, Chughtai B.2, Bojani N.3, Zorn K.3, Elterman D.1

1Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, 2Weill Cornell Medicine, Dept. of Urology, New York City, United States of America, 3University of Montreal, Montreal, Canada

Aims and objectives of this presentation

Is prostate artery embolization (PAE) the future for the treatment of lower urinary tract symptoms secondary to benign prostatic hypertrophy?
Aims and objectives of this presentation

1103

Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: 12 month results of a clinical trial

By: Secco S. 1, Rampoldi A. 2, Brambillasca P.M. 2, Barbosa F. 2, Di Trapani D. 1, Barbieri M. 1, Olivero A. 1, Napoli G. 1, Strada E. 1, Petralia G. 1, Migliorisi C. 2, Vercelli R. 2, Bocciardi A.M. 1, Galfano A. 1

1ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, 2ASST Grande Ospedale Metropolitano Niguarda, Dept. of Interventional Radiology, Milan, Italy

Aims and objectives of this presentation

1104

Four year results of water vapor thermal therapy for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH): What minimal important difference (MID) in symptom relief benefits patient quality of life?

By: McVary K. 1, Rogers T. 2, Roehrborn C. 3

1Stritch School of Medicine, Loyola University Medical Center, Dept. of Urology, Maywood, United States of America, 2NAMSA, Dept. of Biostatistics, Minneapolis, United States of America, 3UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

Aims and objectives of this presentation

1105

Retrograde ejaculation after holmium laser enucleation of the prostate (HOLEP) – evaluation of patient bother and impact on sexual function using validated questionnaires

By: Gild P. 1, Pompe R. 1, Vetterlein M.W. 1, Maurer V. 1, Marks P. 1, Lukas L. 1, Ihab D. 1, Ernst T. 1, Dahlem R. 1, Fisch M. 1, Reiss P. 1, Rink M. 1, Meyer C.P. 1, Becker A. 2

1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Frankfurt University Hospital and University Medical Center Hamburg-Eppendorf, Dept. of Urology, Frankfurt, Germany

Aims and objectives of this presentation

1106
1107  Aquablation for BPH in large prostates (80-150cc): 6-month results from the WATERII multicenter trial

By: Desai M.M., WATERII Study Investigators
University of Southern California, Dept. of Urology, Los Angeles, United States of America

Aims and objectives of this presentation
1107

1108  Predictors of index bladder outlet obstruction procedure care setting and its impact on perioperative outcomes and costs

By: Tully K.1, Friedlander D.2, Krimphove M.3, Noldus J.4, Trinh Q-D.2
1Marien Hospital Herne, Dept. of Urology, Herne, Germany, 2Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, 3University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, 4Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany

Aims and objectives of this presentation
1108

1109  Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation (TULSA): Subgroup analyses in patients with symptoms of benign prostatic hyperplasia

By: Elterman D.1, Hatiboglu G.2, Hetou K.3, Staruch R.4, Burtnyk M.4, Relle J.5, Shepherd S.1, Chin J.3
1Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, 2University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 3Western University, London Health Sciences Centre, Division of Urology, London, Canada, 4Profound Medical, Medical Affairs, Mississauga, Canada, 5Beaumont Health System, Dept. of Urology, Royal Oak, United States of America

Aims and objectives of this presentation
1109

1110  Novel technique in ejaculation preserving trans urethral bipolar prostatectomy: Enucleation and resection modalities

By: Abou Taleb A.A.1, Fathy A.2, Ahmed S.2, Saber W.2, Sebaey A.2, Shaer W.2, Noah K.1, Noureldin Y.2
1Benha University, Uproro medical center, Dept. of Urology, Cairo, Egypt, 2Benha University, Dept. of Urology, Cairo, Egypt

Aims and objectives of this presentation
1110

1111  Ejaculatory hood sparing vs. standard GreenLight™ laser photoselective vaporization of the prostate: Sexual and urodynamic assessment through randomized controlled trial
By: Abolazm A.E., Elshal A.M., El-Hefnawy A.S., Laymon M., Shehab El-Din A.B. Mansoura Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

Aims and objectives of this presentation

1111

**1112**

**ProstaCare: Water electrolysis system for the treatment of benign prostate hyperplasia**

By: Lim Y.W. \(^1\), Tiong H.Y. \(^2\), Chua W.J. \(^2\), Sim S.P.A. \(^1\), Ho S.S.H. \(^1\)

\(^1\)Singapore General Hospital, Dept. of Urology, Singapore, Singapore, \(^2\)National University Hospital, Dept. of Urology, Singapore, Singapore

Aims and objectives of this presentation

1112

**1113**

**Pulling the Foley: Can the prostatic urethral lift be used in men with catheter dependent urinary retention?**

By: McMahon G.C.M. \(^1\), Panuganti S. \(^1\), Wilson M. \(^1\), Thaker T. \(^1\), Mueller T. \(^2\)

\(^1\)Rowan University, Dept. of Urology, Stratford, United States of America, \(^2\)New Jersey Urology, Dept. of Urology, Voorhees, United States of America

Aims and objectives of this presentation

1113

**15:23 - 15:30**

**Summary**

S. Madersbacher, Vienna (AT)